Rx Safety Conundrum: Where Does Labeling Stop And Medical Practice Begin?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee agreed with ISTA Pharmaceuticals that there wasn’t enough safety data to make a decision about the risks associated with using a single bottle of anti-inflammatory eyedrops for both eyes, but decided to come down on the side of caution.